Kalvista Pharmaceuticals Limited

Kalvista Pharmaceuticals Limited focuses its clinical research on Hereditary Angioedema (HAE) Type I and Type II, with studies addressing both adolescent and adult populations as well as younger children. The sponsor’s work centers on treatment options for HAE attacks and on the safety and tolerability of therapies used in this rare immunological disorder.

• HAE Type I and Type II
• Angioedema attack treatment
• Rare disease management

Clinical activity includes research across multiple countries and collaborating sites, reflecting an international focus on hereditary swelling disorders and age-specific therapeutic needs.